March 25, 2025 03:10 PM EDT

Revvity secures $37.8M contract to help screen UK newborns for rare diseases

Jared Whitlock

Features Editor

Diagnostics company Revvity will sequence the DNA of newborns to help identify rare genetic conditions as part of Genomic England’s efforts to bolster early disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Revvity secures $37.8M contract to help screen UK newborns for rare diseases

Jared Whitlock

Features Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Senate confirms Makary as FDA chief with agency cuts, return-to-office in force

Lyndra Therapeutics to wind down amid funding hurdles for long-acting drug technology

Trump tariffs would increase costs for almost every biopharma company, survey claims

Covid contrarian Bhattacharya is confirmed as NIH chief, taking over at a fraught moment for federal research

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

Merck strikes deal for heart drug, worth up to $2B, with China’s Hengrui

Revvi­ty se­cures $37.8M con­tract to help screen UK new­borns for rare dis­eases

Features Editor

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Revvity secures $37.8M contract to help screen UK newborns for rare diseases